By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
News
Donald Trump threatens 100% secondary tariffs on Russia
53 minutes ago
News
Fastenal Company 2025 Q2 – Results – Earnings Call Presentation (NASDAQ:FAST)
1 hour ago
News
Warren Buffett comes out on top from Kraft Heinz flop
2 hours ago
News
Ukraine hits back after top agent assassinated in Kyiv
3 hours ago
News
Volodymyr Zelenskyy nominates new Ukraine PM in major reshuffle
4 hours ago
News
EU warns Trump’s 30% tariffs would eliminate transatlantic trade
6 hours ago
News
Bitcoin hits $120,000 milestone as US Congress readies for ‘crypto week’
7 hours ago
News
European stocks slip after Donald Trump’s tariff threat
8 hours ago
News
Donald Trump says US will send Patriot missiles to Ukraine
9 hours ago
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Him & Hers raises full-year sales outlook, but stock falls
Investing

Him & Hers raises full-year sales outlook, but stock falls

News Room
Last updated: 2023/05/09 at 9:51 AM
By News Room
Share
1 Min Read
SHARE

Hims & Hers Health Inc. HIMS — the wellness company behind the online telehealth and prescription platforms Hims and Hers — on Monday reported a bigger per-share loss than expected for its first quarter, but raised its full-year sales forecast. The company — which offers erectile dysfunction pills, birth control, and anxiety and depression medications — said it expected full-year sales of $810 million to $830 million, compared with an earlier outlook for $735 million to $755 million and FactSet forecasts for $755.3 million. For its first quarter, the company reported a net loss of $10.1 million, or 5 cents a share, compared…

Read the full article here

News Room May 9, 2023 May 9, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Donald Trump threatens 100% secondary tariffs on Russia

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Fastenal Company 2025 Q2 – Results – Earnings Call Presentation (NASDAQ:FAST)

This article was written byFollowSeeking Alpha's transcripts team is responsible for the…

Warren Buffett comes out on top from Kraft Heinz flop

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Ukraine hits back after top agent assassinated in Kyiv

Stay informed with free updatesSimply sign up to the War in Ukraine…

Volodymyr Zelenskyy nominates new Ukraine PM in major reshuffle

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?